Lipocine (LPCN) Common Equity (2011 - 2025)
Lipocine (LPCN) recorded Common Equity of $14.48 million in Q4 2025, down 31.1% from $21 million a year earlier but up 2.4% from the prior quarter.
Powered by 
Analysis
Lipocine (LPCN) Common Equity (2011 - 2025) Analysis & Trends
Starting with Q4 2011, Lipocine's Common Equity history includes 56 quarters.
- Annual Common Equity has a five-year compound annual growth rate of -1.2% (FY2020 to FY2025).
- Across earlier years, Common Equity came in at $21 million in FY2024 (+3.1%), $20.37 million in FY2023 (-42.8%), $35.63 million in FY2022 (-21.8%) and $45.57 million in FY2021 (+197.0%).
- Quarterly Common Equity has ranged from $14.14 million in Q3 2025 to $45.57 million in Q4 2021 over the past five years.
- On a year-over-year basis, Common Equity has declined for four consecutive quarters, with an average decline of 19.9% over the last eight quarters.
- Peak year-over-year performance for Common Equity in the last five years was growth of 546.9% in Q1 2021, against a decline of 42.8% in Q4 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at $14.14 million (Q3 2025), $17.13 million (Q2 2025) and $19.2 million (Q1 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Lipocine | 11.33 Mn | -56.39 Mn | - | 14.48 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 14.48 Mn |
| Sep 30, 2025 | 14.14 Mn |
| Jun 30, 2025 | 17.13 Mn |
| Mar 31, 2025 | 19.20 Mn |
| Dec 31, 2024 | 21.00 Mn |
| Sep 30, 2024 | 19.12 Mn |
| Jun 30, 2024 | 21.21 Mn |
| Mar 31, 2024 | 23.96 Mn |
| Dec 31, 2023 | 20.37 Mn |
| Sep 30, 2023 | 22.48 Mn |
| Jun 30, 2023 | 28.55 Mn |
| Mar 31, 2023 | 31.96 Mn |
| Dec 31, 2022 | 35.63 Mn |
| Sep 30, 2022 | 37.65 Mn |
| Jun 30, 2022 | 39.89 Mn |
| Mar 31, 2022 | 42.41 Mn |
| Dec 31, 2021 | 45.57 Mn |
| Sep 30, 2021 | 32.81 Mn |
| Jun 30, 2021 | 35.75 Mn |
| Mar 31, 2021 | 42.39 Mn |
API Access
Lipocine Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=LPCN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "LPCN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=LPCN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();